The Technical Analyst
Co-Diagnostics Inc [CODX]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Diagnostics & Research
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-6.54% $7.72
Last updated: 21 Jan 2022 @ 12:17 pm
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 225.12 mill |
| EPS: | 1.424 |
| P/E: | 5.42 |
| Earnings Date: | Nov 11, 2021 |
| SharesOutstanding: | 29.16 mill |
| Avg Daily Volume: | 0.702 mill |
| RATING 2022-01-20 |
|---|
| A+ |
| Strong Buy |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.07x |
| Company: PE 5.42 | sector: PE 82.90 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.04x |
| Company: PE 5.42 | industry: PE 123.36 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$9.25 (19.82%) $1.530 |
| Date: 2022-01-21 |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-01-08 | Serbin Richard S | Sell | 12 500 | Restricted Stock Units |
| 2022-01-08 | Serbin Richard S | Buy | 12 500 | Common Stock |
| 2022-01-08 | Nelson James B | Sell | 12 500 | Restricted Stock Units |
| 2022-01-08 | Nelson James B | Buy | 12 500 | Common Stock |
| 2022-01-08 | Murphy Ted | Sell | 12 500 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 6.13 |
| Last 100 transactions |
| Buy: 1 852 123 | Sell: 3 482 713 |
Forecast:
13:56 - $7.76
Live Trading Signals (every 1 min)
Forecast 1: 12:26 - $7.72
Forecast 2: 13:16 - $7.75
Forecast 3: 13:56 - $7.76
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.72 (-6.54% ) |
| Volume | 0.483 mill |
| Avg. Vol. | 0.702 mill |
| % of Avg. Vol | 68.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CODX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
| Date | Signal | @ | Closed | % | Jan 21 - 17:03 | sell | $7.76 | N/A | Active |
|---|
CODX
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Latest Press Releases
2022-01-21 09:30:00 - Press Release
Co-diagnostics, Inc. To Host Booth At Medlab Middle East 2022 In Dubai On January 24-27
Salt lake city, jan. 21, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming medlab middle east 2022 trade show held january 24-27 at the dubai world trade centre. it is expected that the conference, catering to the global medical laboratory community and showcasing the latest in laboratory innovation and technology, will provide opportunities for company representatives and distributors to introduce co-diagnostics products to a wide array of international customers.
2022-01-13 09:30:00 - Press Release
Co-diagnostics, Inc. Jv Cosara Receives Clearance From Indian Regulators For High-risk Hpv Multiplex Test
Salt lake city, jan. 13, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saragene™ human papillomavirus high-risk (hpv-hr) real-time pcr test as an in vitro diagnostic ("ivd"). human papillomavirus ("hpv") is the most common sexually transmissible infection in the world and the cause of almost all cervical cancer worldwide (the 4th deadliest cancer in women), as well as a substantial portion of certain other cancers, totaling over 600,000 cases of cancer per year being attributable to hpv.
2021-12-31 09:30:00 - Press Release
Co-diagnostics, Inc. Announces Completion Of The Acquisition Of All Assets And Intellectual Property Related To At-home/point-of-care Platform
Salt lake city, dec. 31, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the acquisition of idaho molecular inc. and advanced conceptions, inc. for nearly 4.72 million shares of the company's stock, plus additional common warrants totaling 465,000, providing co-diagnostics with all existing and future assets and intellectual property related to the company's upcoming at-home/point-of-care diagnostic device. the acquisition, first announced on december 22 , is expected to streamline the commercialization of the eikon™ platform and yourtest™ pcr device as it nears completion.
2021-12-22 09:25:00 - Press Release
Co-diagnostics, Inc. Signs Agreement To Acquire All Assets And Intellectual Property Related To At-home/point-of-care Platform
Salt lake city, dec. 22, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has entered into definitive agreements with each of idaho molecular inc. and advanced conceptions, inc., pursuant to which each of them will become wholly owned subsidiaries of co-dx. co-dx has been working with idaho molecular and advanced conceptions on the development of co-diagnostics' upcoming at-home/point-of-care diagnostic device.
2021-12-07 09:25:00 - Press Release
Co-diagnostics Jv Cosara Receives Clearance From Indian Regulators For Abc Multiplex Test
Salt lake city, dec. 7, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saraplex™ flu a/flu b/covid-19 (abc) rt-pcr test as an in vitro diagnostic ("ivd"). cosara's new test, the 4th cosara assay to receive cdsco approval this year and 11th overall, is built on the company's patented coprimer™ technology and designed for the simultaneous detection and differentiation of influenza a, influenza b, and sars-cov-2.
Latest News
2022-01-05 14:30:13 - GuruFocus
4 Stocks With High Growth Potential
Choosing U.S.-listed equities that have the characteristics listed below represents an arguably solid starting point when screening the market for potential value opportunities:
2021-12-31 10:26:40 - Proactive Investors
Co-Diagnostics completes acquisition of Idaho Molecular and Advanced Conception to expand its at-home/point-of-care diagnostic device
Co-Diagnostics (NASDAQ:CODX) Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intellectual property related to its upcoming at-home/point-of-care diagnostic device. The transaction was settled for 4.72 million shares of Co-Diagnostics (NASDAQ:CODX) stock, and additional common warrants totaling 465,000.
2021-12-31 05:56:00 - The Motley Fool
Why Co-Diagnostics, Ocugen, and Sorrento Stocks Are Sinking This Week
2021-12-27 16:21:13 - The Motley Fool
Why Co-Diagnostics Stock Rose 15.8% on Monday
The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.
2021-12-22 10:00:53 - Proactive Investors
Co-Diagnostics fighting coronavirus (COVID-19) with flagship test, plans at-home PCR-based platform
Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does: Co-Diagnostics Inc is a molecular diagnostics company that develops products to detect infectious diseases in humans and animals. The company also develops tools for liquid-biopsy cancer screening and agricultural uses.
2021-12-22 10:00:51 - Proactive Investors
Co-Diagnostics to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform
Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.
2021-12-22 09:58:57 - Proactive Investors
Co-Diagnostics signs agreement to acquire Idaho Molecular and Advanced Conception for its at-home/point-of-care platform
Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnostic device. The Utah-based company said that the transactions will provide it with all the existing and future assets and intellectual property related to the upcoming platform.
2021-12-13 16:18:39 - InvestorPlace
7 Stocks to Buy to Hedge Against Omicron Variant Risks
With the omicron variant presenting uncertainties regarding how governments will react, here are some stocks to buy to counter that risk. The post 7 Stocks to Buy to Hedge Against Omicron Variant Risks appeared first on InvestorPlace.
2021-12-07 16:33:00 - Proactive Investors
Co-Diagnostics partners with TiiCKER to increase connection with retail investors
Co-Diagnostics (NASDAQ:CODX) Inc said it has partnered with TiiCKER—a consumer shareholder loyalty platform—to increase its connection to retail investors. The Salt Lake City-based company has teamed up with TiiCKER to reach new and existing investors, verify its shareholders and stock perks, and connect with retail investors interested in learning more about its world-class testing services and technology.
2021-11-29 11:35:19 - Benzinga
Co-Diagnostics Stock Sees Movement After Company Says Products Unaffected By Omicron Variant
Co-Diagnostics Inc. (NASDAQ:CODX) shares gapped higher Monday, but have since fallen and are now trading lower. The company said today its COVID-19 diagnostics are not affected by the omicron variant.